Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 8910 participants.

Also called NCT01601704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 8,910 participants (enrolled count) (from the registry)
Sponsor
Orexigen Therapeutics, Inc (from the registry)
Registry
  • NCT NCT01601704
  • WHO UTN U1111-1162-4981
Other papers using this trial's data
  • Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial JAMA, 2016-03-08 DOI, PubMed 26954408

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01601704. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2017-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
Condition
Obesity
Condition
Overweight
Intervention (Drug)
NB32
Intervention (Drug)
PBO
Intervention (Behavioral)
Weight Management Program
Lead sponsor
Orexigen Therapeutics, Inc (class: industry)

Record details

Record id
cardio:ct-nct01601704
Content hash
c675f911d54df38328587ff57174eb2d4c494e620d2de3d23f5c451b7b469a49